Raajit K. Rampal, MD, PhD, discusses some of the promising emerging therapies for myelofibrosis that target different pathways at the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, hosted by Dr. Guenther Koehne and Miami Cancer Institute.
Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses some of the promising emerging therapies for myelofibrosis that target different pathways at the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, hosted by Dr. Guenther Koehne and Miami Cancer Institute.
In the myelofibrosis treatment landscape, ruxolitinib (Jakafi) is an established JAK inhibitor, along with newer JAK inhibitors like fedratinib (Inrebic) and momelotinib (Ojjaara). Research continues to evaluate new options, including navitoclax.
He then moves into an overview of some of the significant and ongoing clinical trials that are currently investigating new treatment approaches for patients with myelofibrosis. Specifically, Rampal highlights important phase 3 trials that have had their 6-month readouts, highlighting the need for further follow-up to look at progression-free survival, overall survival, duration of response, and more.
Transcription:
0:09 | We are in a situation where there are a lot of novel and interesting therapies. Right now, phase 3 data has just [been] reported out on pelabresib [CPI-0610], which is a BET inhibitor, as navitoclax, which is the BCL-xL inhibitor, [and] both look really promising. There are things in earlier phases as well like PIM kinase inhibitors, we also have things like MDM2 inhibitors, and now we are at the advent of potentially having immunotherapies with antibodies in the market called calreticulin, which is really exciting.
0:40 | I think there are a number of [significant clinical trials]. As I mentioned, there are phase 3 trials that have had their 6 month readout. We have got to see what happens with longer-term follow-up, does it change progression-free survival, overall survival, the depth of response, to the duration of response? All of those things remain to be determined. Of course, there are a number of earlier phase trials that are ongoing.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More